查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1723660

RSV疫苗市場:疫苗類別，各給藥途徑，對象患者層，各流通管道，主要各地區，各主要企業:2040年為止的產業趨勢與全球預測

RSV Vaccine Market by Type of Vaccine, Route of Administration, Target Patient Population, Distribution Channel, Key Geographical Regions, and Leading Players: Industry Trends and Global Forecasts, till 2040
出版日期: | 出版商: Roots Analysis | 英文 378 Pages | 商品交期: 最快1-2個工作天內

價格

RSV 疫苗市場

今年全球 RSV 疫苗市場規模為 11.49 億美元。預計到2040年，市場規模將達到7.31億美元。

呼吸道合胞病毒（RSV）疫苗市場機會分佈在以下領域：

疫苗類型

  • 次單元/類病毒顆粒(VLP)疫苗
  • 活病毒疫苗
  • mRNA疫苗

給藥途徑

  • 肌肉內
  • 其他

對象患者層

  • 老年人
  • 嬰幼兒/兒童
  • 孕婦

流通管道

  • 藥局·藥店
  • 政府/機關供應商
  • 其他

主要地區

  • 北美
  • 歐洲

呼吸道合胞病毒 (RSV) 疫苗市場：成長與趨勢

呼吸道合胞病毒 (RSV) 是一種常見病毒，會在嬰兒、老年人和免疫功能低下人群中傳播下呼吸道感染。該病毒被認為是一種高度傳染性的呼吸道病原體，在世界各地導致嚴重疾病和死亡。根據世界衛生組織統計，全球每年約有 3,300 萬例 5 歲以下兒童新發 RSV 感染病例。這是由於缺乏有效的 RSV 感染治療方法。

目前，包括非處方藥、滴鼻劑和加濕器在內的多種預防方法被用於治療 RSV 感染。然而，這些只是症狀治療，因此疫苗因其為患者提供安全有效的針對性治療而成為一種有前景的選擇。這些疫苗有望最大程度地降低呼吸道合胞病毒感染以及支氣管炎和肺炎等呼吸道疾病相關的住院率、併發症和死亡率。

RSV Vaccine Market-IMG1

由於 mRNA 和奈米顆粒技術等技術進步，這些疫苗能夠提供長期免疫力並有效治療呼吸道合胞病毒感染。此外，隨著研發投入和 RSV 治療臨床試驗數量的增加，預計 RSV 疫苗的需求將會增加，這可能會推動市場在未來幾年實現健康成長。

呼吸道合胞病毒 (RSV) 疫苗市場：關鍵洞察

本報告分析了呼吸道合胞病毒 (RSV) 疫苗市場的現狀，並探討了該行業的潛在成長機會。主要發現包括：

  • 目前，有超過 70 種呼吸道合胞病毒 (RSV) 疫苗正在使用各種技術進行研發，其中超過 60% 的疫苗正處於不同的臨床試驗階段。
RSV Vaccine Market-IMG2
  • 呼吸道合胞病毒 (RSV) 疫苗需求的不斷增長促使疫苗研發管線顯著增加，目前約有 65 種疫苗處於臨床前和臨床研發階段。
  • 超過 85% 的呼吸道合胞病毒 (RSV) 疫苗臨床試驗由業內公司贊助。
RSV Vaccine Market-IMG3
  • 自 2020 年以來，RSV 疫苗領域已提交/授予超過 330 項專利，其中大部分專利申請於北美（超過 50%）。
  • 日益嚴重的呼吸道合胞病毒感染疫情和技術進步的步伐加快，推動著 RSV 疫苗市場的發展，預計該市場在短期內將實現穩步增長。
  • 預計 RSV 疫苗市場的整體機會將涵蓋各個關鍵地區、疫苗類型、給藥途徑、目標患者群體和分銷管道。
RSV Vaccine Market-IMG4

RSV 疫苗市場：主要細分市場

依疫苗類型，全球 RSV 疫苗市場分為次單位/病毒樣顆粒 (VLP) 疫苗、減毒活疫苗和 mRNA 疫苗。目前，亞單位/病毒樣顆粒 (VLP) 疫苗佔據 RSV 疫苗市場的大部分佔有率。這是因為這些疫苗在形態上與母體病毒相似，產生強烈的免疫原性反應。

依給藥途徑，全球 RSV 疫苗市場分為肌肉注射和其他途徑。目前，透過肌肉注射途徑接種的疫苗可能佔據整個市場的主導地位。這歸功於其高生物利用度，確保高效吸收並減少副作用，使其成為患者更安全、更有效的選擇。

全球呼吸道合胞病毒疫苗市場按目標患者族群細分為老年人、嬰幼兒及孕婦。目前，呼吸道合胞病毒疫苗市場將以老年人群為主。這是因為老年人極易感染呼吸道疾病，尤其是在呼吸道合胞病毒高發生期。

全球呼吸道合胞病毒疫苗市場按分銷管道細分為藥局、政府和機構供應商以及其他管道。值得注意的是，在預測期內，藥局通路很可能佔據呼吸道合胞病毒疫苗市場的主導地位。這是因為該疫苗接種方便、普及，且藥師對疫苗接種的認可度不斷提高，從而推動了疫苗接種率的提高。

依主要地區劃分，市場分為北美和歐洲。目前，北美佔據最大的市場佔有率，這歸因於該地區呼吸道感染病例的不斷增加、完善的監管框架以及先進的醫療基礎設施。

報告解答的關鍵問題

  • 目前有多少家公司進入該市場？
  • 該市場的主要公司
  • 可能影響該市場發展的因素
  • 當前與未來的市場規模
  • 該市場的複合年增長率
  • 當前和未來的市場機會如何在主要細分市場中分配？
  • 市場專利申請趨勢

為何購買此報告？

  • 本報告提供全面的市場分析，並針對整體市場和特定細分市場提供詳細的收入預測。這些資訊對於現有的市場領導者和新進入者都極具價值。
  • 利害關係人可以利用本報告深入了解市場競爭動態。分析競爭格局有助於企業做出明智的決策，優化市場定位，並制定有效的市場進入策略。
  • 本報告為利害關係人提供了全面的市場概覽，包括關鍵推動因素、阻礙因素和挑戰。這些資訊使利害關係人能夠掌握市場趨勢，並做出基於數據的決策，從而掌握成長前景。

更多優勢

  • 報告中所有分析模組均提供免費 Excel 資料包
  • 10% 免費內容客製化
  • 由我們的研究團隊提供詳細的報告講解
  • 如果報告發佈時間超過 6-12 個月，則可免費更新報告

按本報告提供全球RSV疫苗市場相關調查，提供市場概要，以及疫苗類別，各給藥途徑，對象患者層，各流通管道，主要各地區，各主要企業趨勢，及加入此市場的主要企業簡介等資訊。

目錄

章節I:報告概要

第1章 背景

第2章 調查手法

第3章 市場動態

第4章 宏觀經濟指標

章節II:定性性的洞察

第5章 摘要整理

第6章 簡介

  • 呼吸道融合病毒（RSV）疫苗的簡介
  • RSV的結構與機制
  • 呼吸道融合病毒（RSV）疫苗相關的主要歷史的事件
  • 呼吸道融合病毒（RSV）疫苗類型
  • 呼吸道融合病毒（RSV）疫苗接種的優點
  • 呼吸道融合病毒（RSV）疫苗伴隨開發的課題
  • 未來展望

章節III:市場概要

第7章 市場形勢

  • 呼吸道融合病毒（RSV）疫苗:市場形勢

第8章 產品競爭力分析

  • 前提主要的參數
  • 調查手法
  • 呼吸道融合病毒（RSV）疫苗:產品競爭力分析

章節IV:企業簡介

第9章 企業簡介北美的呼吸道融合病毒（RSV）疫苗開發企業

  • Icosavax(A Company of AstraZeneca)
  • Moderna
  • Pfizer

第10章 企業簡介:歐洲的RSV疫苗開發企業

  • GlaxoSmithKline
  • Sanofi

第11章 企業簡介:亞太地區的RSV疫苗開發企業

  • Beijing Advaccine Biotechnology

第5章 市場趨勢

第12章 臨床試驗的分析

  • 範圍調查手法
  • 呼吸道融合病毒（RSV）疫苗:臨床試驗分析

第13章 專利分析

第14章 FDA核准策略

章節VI:市場機會分析

第15章 市場影響分析:促進因素，阻礙因素，機會，課題

  • 市場促進因素
  • 市場阻礙因素
  • 市場機會
  • 市場課題

第16章 全球RSV疫苗市場

第17章 呼吸道融合病毒（RSV）疫苗市場(疫苗類別)

第18章 呼吸道融合病毒（RSV）疫苗市場(各給藥途徑)

第19章 呼吸道融合病毒（RSV）疫苗市場(對象患者層)

第20章 呼吸道融合病毒（RSV）疫苗市場(各流通管道)

第21章 呼吸道融合病毒（RSV）疫苗市場(主要各地區)

第22章 市場集中分析(主要加入企業)

章節VII:地理地區的市場機會分析

第23章 市場機會分析:北美

第24章 市場機會分析:歐洲

章節VIII:其他的壟斷的洞察

第25章 結論

第26章 執行洞察

章節IX:附錄

第27章 表格形式資料

第28章 企業·團體一覽

Product Code: RA100525

RSV VACCINE MARKET

As per Roots Analysis, the global RSV vaccine market size is worth USD 1,149 million in the current year and is expected to be worth USD 731 million by 2040.

The opportunity for RSV vaccine market has been distributed across the following segments:

Type of Vaccine

  • Subunit / Viral-like-Particle (VLP) Vaccines
  • Live Attenuated Vaccines
  • mRNA Vaccines

Route of Administration

  • Intramuscular
  • Other Routes

Target Patient Population

  • Elderly Individuals
  • Infants / Children
  • Pregnant Individuals

Distribution Channel

  • Pharmacies and Drug Stores
  • Government / Institutional Suppliers
  • Others

Key Geographical Regions

  • North America
  • Europe

RSV VACCINE MARKET: GROWTH AND TRENDS

Respiratory Syncytial Virus (RSV) is a common virus spreading lower respiratory tract infections in infants, older adults, and immunocompromised individuals. This virus is recognized as a highly contagious respiratory pathogen, which contributes to severe illness and mortality across the globe. According to the WHO, around 33 million new cases of RSV infections are emerging annually in children under the age of five across the globe. This can be attributed to the lack of effective treatment options for RSV infections.

Currently, several preventive measures, such as over-the-counter medications, nasal sprays, and humidifiers are being used for the treatment of RSV infections. However, they only provide symptomatic relief, making vaccines a promising alternative that offers safe, effective and targeted treatment to patients. These vaccines have the potential to minimize hospitalization rates, complications, and mortality rates related to RSV infections as well as other respiratory illnesses, such as bronchitis and pneumonia.

RSV Vaccine Market - IMG1

Driven by technological advancements, including the use of mRNA and nanoparticle technology for developing RSV vaccines, these vaccines are providing long lasting immunity and effective treatment against RSV infections. Moreover, owing to the increased research and development efforts and rising number of clinical trials for RSV treatment, the demand for RSV vaccines is anticipated to rise, positioning the market for healthy growth in the forthcoming years.

RSV VACCINE MARKET: KEY INSIGHTS

The report delves into the current state of the RSV vaccine market and identifies potential growth opportunities within the industry. Some key findings from the report include:

  • Presently, more than 70 RSV vaccines are being developed using various technologies; notably, over 60% of these vaccines are under investigation in different clinical trial phases.
RSV Vaccine Market - IMG2
  • The rising demand for RSV vaccines has led to a notable increase in the vaccine pipeline, with around 65 vaccines currently under preclinical and clinical stages of development.
  • A sizeable increase in the number of registered clinical trials has been observed in recent years; over 85% of the trials evaluating RSV vaccines have been sponsored by industry players.
RSV Vaccine Market - IMG3
  • Since 2020, more than 330 patents have been filed / granted in the RSV vaccines domain; further, the majority of the patents were filed in North America (>50%).
  • The growing prevalence of respiratory syncytial virus infections, coupled with the increasing pace of technological advancements is driving the RSV vaccines market and positioning it for steady growth in the foreseeable future.
  • The overall opportunity within the RSV vaccine market is anticipated to be well distributed across various key geographical regions, types of vaccines, routes of administration, target patient populations and distribution channels.
RSV Vaccine Market - IMG4

RSV VACCINE MARKET: KEY SEGMENTS

Subunit / Viral-Like-Particle (VLP) Vaccines are Likely to Dominate the RSV Vaccine Market During the Forecast Period

Based on the types of vaccines, the global RSV vaccine market is segmented into subunit / viral-like-particle (VLP) vaccines, live attenuated vaccines and mRNA vaccines. Currently, the majority share of the RSV vaccine market is captured by subunit / Viral-Like-Particle (VLP) vaccines, owing to the strong immunogenic response produced by these vaccines since they are morphologically similar to their parent virus.

Vaccines Administered through Intramuscular Route are Likely to Hold the Largest Share of the RSV Vaccine Market during the Forecast Period

Based on the route of administration, the global RSV vaccine market is distributed across intramuscular and other routes. Currently, the vaccines administered through the intramuscular route are likely to dominate the overall market. This can be attributed to their high bioavailability, which ensures efficient absorption, along with reduced side effects, making them a safer and more effective option for patients.

By Target Patient Population, RSV Vaccines Developed for Elderly Individuals are Likely to Dominate the Market during the Forecast Period

Based on the target patient population, the global RSV vaccine market is segmented into elderly individuals, infants / children and pregnant individuals. The current RSV vaccine market is likely to be dominated by elderly individuals' segment. This can be attributed to the fact that elderly individuals are highly susceptible to respiratory diseases, specifically during RSV season.

By Type of Material, Stainless Steel Segment is Likely to Dominate the Market During the Forecast Period

Based on the distribution channel, the global RSV vaccine market is segmented into pharmacies and drug stores, government / institutional suppliers and others. Notably, the pharmacies and drug stores segment are likely to dominate the RSV vaccine market during the forecast period. This can be attributed to their convenience and widespread accessibility, along with the rising authorization of pharmacists to administer vaccines which has contributed to increased vaccination rates.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America and Europe. In the current scenario, North America is likely to capture the largest market share which can be attributed to the growing incidences of respiratory infections, robust regulatory frameworks, and advanced healthcare infrastructure in this region.

Example Players in the RSV Vaccine Market

  • AIM Vaccine
  • Beijing Advaccine Biotechnology
  • CureVac
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Icosavax (A company of AstraZeneca)
  • Johnson & Johnson
  • KM Biologics
  • MedImmune (A part of AstraZeneca)
  • Moderna
  • Pfizer
  • Sanofi
  • SK Bioscience

RSV VACCINE MARKET: RESEARCH COVERAGE

The report on the RSV vaccine market features insights on various sections, including:

  • Market Sizing and Opportunity Analysis: An in-depth analysis of the RSV vaccine market, focusing on key market segments, including [A] type of vaccine, [B] route of administration, [C] target patient population, [D] distribution channel, and [E] key geographical regions and [F] leading players.
  • Market Impact Analysis: A thorough analysis of various factors, such as drivers, restraints, opportunities, and existing challenges that are likely to impact market growth.
  • RSV Vaccines Market Landscape: A comprehensive evaluation of various RSV vaccines, based on several relevant parameters, such as [A] stage of development, [B] route of administration, [C] type of vaccine, [D] type of protein targeted, [E] type of immunization, and [F] target patient population. This section also includes an evaluation of the companies engaged in developing RSV vaccines, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters.
  • Product Competitiveness Analysis: An insightful competitiveness analysis of various RSV vaccines based on various relevant parameters, such as [A] developer strength, [B] product competitiveness, and [C] portfolio diversity.
  • Company Profiles: Elaborate profiles of prominent RSV vaccine developers across various geographies, including North America, Europe, Asia-Pacific, providing details on [A] company overview, [B] financial information (if available), [C] product portfolio, [D] recent developments and [E] an informed future outlook.
  • Clinical Trial Analysis: A detailed assessment of clinical trials that have been published for various types of RSV vaccines, based on various relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] study design, [E] type of sponsor / collaborator, [F] gender, [G] target patient population, [H] leading players and [I] geography.
  • Patent Analysis: An in-depth analysis of patents filed / granted till date in the RSV vaccine domain, based on various relevant parameters, such as [A] type of patent, [B] publication year, [C] patent application year, [D] CPC symbols, [E] patent jurisdiction, [F] type of applicant, [G] leading industry players, [H] leading industry players, [I] patent benchmarking, [J] patent age, and [K] patent valuation analysis.
  • FDA Approval Strategies: A detailed overview of various competitive strategies that can be incorporated by the RSV vaccine developers in order to expedite the FDA approval process of their proprietary vaccines. The section also provides information on several stakeholders undertaking various initiatives, including awards / grants, partnerships, and expanding intellectual properties.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What is the patent filing activity trend in the market?

REASONS TO BUY THIS REPORT

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 10% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

SECTION I: REPORT OVERVIEW

1. BACKGROUND

  • 1.1. Context
  • 1.2. Project Objectives

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations in the Industry
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

  • 6.1. Introduction to RSV Vaccines
  • 6.2. Structure and Mechanism of RSV
  • 6.3. Key Historical Events Related to RSV Vaccines
  • 6.4 Types of RSV Vaccines
    • 6.4.1. Nucleic Acid Based Vaccines
    • 6.4.2. Protein Based Vaccines
    • 6.4.3. Recombinant Vector Based Vaccines
    • 6.4.4. Live Attenuated Vaccines
  • 6.5. Benefits of RSV Vaccination
  • 6.6. Challenges Associated with Development of RSV Vaccines
  • 6.7. Future Perspectives

SECTION III: MARKET OVERVIEW

7. MARKET LANDSCAPE

  • 7.1. RSV Vaccines: Overall Market Landscape
    • 7.1.1. Analysis by Stage of Development
    • 7.1.2. Analysis by Route of Administration
    • 7.1.3. Analysis by Type of Vaccine
    • 7.1.4. Analysis by Type of Protein Targeted
    • 7.1.5. Analysis by Type of Immunization
    • 7.1.6. Analysis by Target Patient Population
    • 7.1.7. Analysis by Year of Establishment
    • 7.1.8. Analysis by Company Size
    • 7.1.9. Analysis by Location of Headquarters

8. PRODUCT COMPETITIVENESS ANALYSIS

  • 8.1. Assumptions and Key Parameters
  • 8.2. Methodology
  • 8.3. RSV Vaccines: Product Competitiveness Analysis
    • 8.3.1. RSV Vaccines Developed by Players Based in North America
    • 8.3.2. RSV Vaccines Developed by Players Based in Europe
    • 8.3.3. RSV Vaccines Developed by Players Based in Asia-Pacific and Rest of the World

SECTION IV: COMPANY PROFILES

9. COMPANY PROFILES: RSV VACCINE DEVELOPERS IN NORTH AMERICA

  • 9.1. Icosavax (A Company of AstraZeneca)
    • 9.1.1. Company Details
    • 9.1.2. Product Portfolio
    • 9.1.3. Recent Developments and Future Outlook
  • 9.2. Moderna
    • 9.2.1. Company Details
    • 9.2.2. Product Portfolio
    • 9.2.3. Financial Details, FY 2021 onwards (USD Million)
    • 9.2.4. Recent Developments and Future Outlook
  • 9.3. Pfizer
    • 9.3.1. Company Details
    • 9.3.2. Product Portfolio
    • 9.3.3. Financial Details, FY 2021 onwards (USD Million)
    • 9.3.4. Recent Developments and Future Outlook

10. COMPANY PROFILES: RSV VACCINE DEVELOPERS IN EUROPE

  • 10.1. GlaxoSmithKline
    • 10.1.1. Company Details
    • 10.1.2. Product Portfolio
    • 10.1.3. Financial Details, FY 2021 onwards (EUR Million)
    • 10.1.4. Recent Developments and Future Outlook
  • 10.2. Sanofi
    • 10.2.1. Company Details
    • 10.2.2. Product Portfolio
    • 10.2.3. Financial Details, FY 2021 onwards (EUR Million)
    • 10.2.4. Recent Developments and Future Outlook

11. COMPANY PROFILES: RSV VACCINE DEVELOPERS IN ASIA-PACIFIC

  • 11.1. Beijing Advaccine Biotechnology
    • 11.1.1. Company Details
    • 11.1.2. Product Portfolio

SECTION V: MARKET TRENDS

12. CLINICAL TRIALS ANALYSIS

  • 12.1. Scope and Methodology
  • 12.2. RSV Vaccines: Clinical Trial Analysis
    • 12.2.1. Analysis by Trial Registration Year, Since 2015
    • 12.2.2. Analysis by Trial Status
    • 12.2.3. Analysis of Enrolled Patient Population by Trial Registration Year, Since 2015
    • 12.2.4. Analysis by Trial Registration Year and Trial Status, Since 2015
    • 12.2.5. Analysis by Trial Phase
    • 12.2.6. Analysis of Enrolled Patient Population by Trial Phase
    • 12.2.7. Analysis by Study Design
    • 12.2.8. Analysis by Type of Sponsor / Collaborator
    • 12.2.9. Analysis by Gender
    • 12.2.10. Analysis by Target Patient Population
    • 12.2.11. Leading Players: Analysis by Number of Registered Trials
    • 12.2.12. Analysis by Geography
    • 12.2.13. Analysis by Trial Status and Geography
    • 12.2.14. Analysis of Enrolled Patient Population by Trial Status and Geography

13. PATENT ANALYSIS

  • 13.1. Scope and Methodology
  • 13.2. RSV Vaccines: Patent Analysis
    • 13.2.1. Analysis by Patent Publication Year, Since 2020
    • 13.2.2. Analysis by Type of Patent
    • 13.2.3. Analysis by Type of Patent and Publication Year, Since 2020
    • 13.2.4. Analysis by Patent Application Year, Since 2008
    • 13.2.5. Analysis by Patent Age
    • 13.2.6. Analysis by Type of Applicant
    • 13.2.7. Analysis by Patent Jurisdiction
    • 13.2.8. Analysis by CPC Symbols
    • 13.2.9. Leading Industry Players: Analysis by Number of Patents
    • 13.2.10. Leading Non-Industry Players: Analysis by Number of Patents
    • 13.2.11. Leading Inventors: Analysis by Number of Patents
  • 13.3. Patent Benchmarking Analysis
    • 13.3.1. Analysis of Patent Characteristics (CPC Codes) by Leading Industry Players
    • 13.3.2. Analysis of Leading Industry Players by Patent Characteristics (CPC Codes)
  • 13.4. Patent Valuation
  • 13.5. Leading Patents by Number of Citations

14. FDA APPROVAL STRATEGIES

  • 14.1. Chapter Overview
  • 14.2. Methodology
  • 14.3. Key Parameters
  • 14.4. General Reasons for Failure of Trials Focused on RSV vaccines
  • 14.5. Benchmarking Analysis: Distribution of Key Strategies by Vaccines

SECTION VI: MARKET OPPORTUNITY ANALYSIS

15. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 15.1. Market Drivers
  • 15.2. Market Restraints
  • 15.3. Market Opportunities
  • 15.4. Market Challenges

16. GLOBAL RSV VACCINE MARKET

  • 16.1. Key Assumptions and Methodology
  • 16.2. Global RSV Vaccine Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 16.2.1. Multivariate Scenario Analysis
      • 16.2.1.1. Conservative Scenario
      • 16.2.1.2. Optimistic Scenario
  • 16.3. Key Market Segmentations

17. RSV VACCINE MARKET, BY TYPE OF VACCINE

  • 17.1. Key Assumptions and Methodology
  • 17.2. RSV Vaccine Market: Distribution by Type of Vaccine
    • 17.2.1. RSV Vaccine Market for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 17.2.2. RSV Vaccine Market for Live Attenuated Vaccines, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 17.2.3. RSV Vaccine Market for mRNA Vaccines, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
  • 17.3. Data Triangulation and Validation

18. RSV VACCINE MARKET, BY ROUTE OF ADMINISTRATION

  • 18.1. Key Assumptions and Methodology
  • 18.2. RSV Vaccine Market: Distribution by Route of Administration
    • 18.2.1. RSV Vaccine Market for Intramuscular, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 18.2.2. RSV Vaccine Market for Other Routes, Historical Trends (Since2023) and Forecasted Estimates Till 2040) (USD Million)
  • 18.3. Data Triangulation and Validation

19. RSV VACCINE MARKET, BY TARGET PATIENT POPULATION

  • 19.1. Key Assumptions and Methodology
  • 19.2. RSV Vaccine Market: Distribution by Target Patient Population
    • 19.2.1. RSV Vaccine Market for Elderly Individuals, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 19.2.2. RSV Vaccine Market for Infants / Children, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 19.2.3. RSV Vaccine Market for Pregnant Individuals, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
  • 19.3. Data Triangulation and Validation

20. RSV VACCINE MARKET, BY DISTRIBUTION CHANNEL

  • 20.1. Key Assumptions and Methodology
  • 20.2. RSV Vaccine Market: Distribution by Distribution Channel
    • 20.2.1. RSV Vaccine Market for Pharmacies and Drug Stores, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 20.2.2. RSV Vaccine Market for Government / Institutional Suppliers, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 20.2.3. RSV Vaccine Market for Others, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
  • 20.3. Data Triangulation and Validation

21. RSV VACCINE MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 21.1. Key Assumptions and Methodology
  • 21.2. RSV Vaccine Market: Distribution by Key Geographical Regions
    • 21.2.1. RSV Vaccine Market in North America, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
    • 21.2.2. RSV Vaccine Market in Europe, Historical Trends (Since2023) and Forecasted Estimates (Till 2040) (USD Million)
  • 21.3. Market Movement Analysis
  • 21.4. Penetration-Growth (P-G) Matrix
  • 21.5. Data Triangulation and Validation

22. MARKET CONCENTRATION ANALYSIS: DISTRIBUTION BY LEADING PLAYERS

  • 22.1. Key Assumptions and Methodology
  • 22.2. RSV Vaccine Market: Leading RSV Vaccines Developers
  • 22.3. Data Triangulation and Validation

SECTION VII: MARKET OPPORTUNITY ANALYSIS WITHIN GEOGRAPHICAL REGIONS**

23. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

  • 23.1. RSV Vaccine Market in North America: Distribution by Type of Vaccine
    • 23.1.1. RSV Vaccine Market in North America for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.1.2. RSV Vaccine Market in North America for Live Attenuated Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.1.3. RSV Vaccine Market in North America for mRNA Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • 23.2. RSV Vaccine Market in North America: Distribution by Route of Administration
    • 23.2.1. RSV Vaccine Market in North America for Intramuscular, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.2.2. RSV Vaccine Market in North America for Other Routes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • 23.3. RSV Vaccine Market in North America: Distribution by Target Patient Population
    • 23.3.1. RSV Vaccine Market in North America for Elderly Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.3.2. RSV Vaccine Market in North America for Infants / Children, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.3.3. RSV Vaccine Market in North America for Pregnant Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • 23.4. RSV Vaccine Market in North America: Distribution by Distribution Channel
    • 23.4.1. RSV Vaccine Market in North America for Pharmacies and Drug Stores, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.4.2. RSV Vaccine Market in North America for Government / Institutional Suppliers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 23.4.3. RSV Vaccine Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)

24. MARKET OPPORTUNITY ANALYSIS: EUROPE

  • 24.1. RSV Vaccine Market in Europe: Distribution by Type of Vaccine
    • 24.1.1. RSV Vaccine Market in Europe for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.1.2. RSV Vaccine Market in Europe for Live Attenuated Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.1.3. RSV Vaccine Market in Europe for mRNA Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • 24.2. RSV Vaccine Market in Europe: Distribution by Route of Administration
    • 24.2.1. RSV Vaccine Market in Europe for Intramuscular, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.2.2. RSV Vaccine Market in Europe for Other Routes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • 24.3. RSV Vaccine Market in Europe: Distribution by Target Patient Population
    • 24.3.1. RSV Vaccine Market in Europe for Elderly Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.3.2. RSV Vaccine Market in Europe for Infants / Children, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.3.3. RSV Vaccine Market in Europe for Pregnant Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • 24.4. RSV Vaccine Market in Europe: Distribution by Distribution Channel
    • 24.4.1. RSV Vaccine Market in Europe for Pharmacies and Drug Stores, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.4.2. RSV Vaccine Market in Europe for Government / Institutional Suppliers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
    • 24.4.3. RSV Vaccine Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040)
  • *Detailed information on Section VII is available in the Excel Data Packs shared along with the report**

SECTION VIII: OTHER EXCLUSIVE INSIGHTS

25. CONCLUSION

26. EXECUTIVE INSIGHTS

SECTION IX: APPENDIX

27. TABULATED DATA

28. LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

  • Table 7.1 RSV Vaccines: Information on Developer, Stage of Development, Route of Administration and Type of Vaccine
  • Table 7.2 RSV Vaccines: Information on Type of Protein Targeted, Type of Immunization and Target Patient Population
  • Table 7.3 RSV Vaccines: List of Developers
  • Table 9.1 Icosavax (A Company of AstraZeneca): Product Portfolio
  • Table 9.2 Moderna: Product Portfolio
  • Table 9.3 Pfizer: Product Portfolio
  • Table 10.1 GlaxoSmithKline: Product Portfolio
  • Table 10.2 Sanofi: Product Portfolio
  • Table 11.1 Beijing Advaccine Biotechnology: Product Portfolio
  • Table 13.1 RSV Vaccine Market: List of Published Patents
  • Table 23.1 RSV Vaccine Market in North America: Distribution by Type of Vaccine, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 23.2 RSV Vaccine Market in North America: Distribution by Route of Administration, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 23.3 RSV Vaccine Market in North America: Distribution by Target Patient Population, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 23.4 RSV Vaccine Market in North America: Distribution by Distribution Channel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 24.1 RSV Vaccine Market in Europe: Distribution by Type of Vaccine, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 24.2 RSV Vaccine Market in Europe: Distribution by Route of Administration, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 24.3 RSV Vaccine Market in Europe: Distribution by Target Patient Population, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 24.4 RSV Vaccine Market in Europe: Distribution by Distribution Channel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • *Detailed information on Tables 23.1-24.4 is available in the Excel Data Packs shared along with the report
  • Table 27.1 RSV Vaccines: Distribution by Stage of Development
  • Table 27.2 RSV Vaccines: Distribution by Route of Administration
  • Table 27.3 RSV Vaccines: Distribution by Type of Vaccine
  • Table 27.4 RSV Vaccines: Distribution by Type of Protein Targeted
  • Table 27.5 RSV Vaccines: Distribution by Type of Immunization
  • Table 27.6 RSV Vaccines: Distribution by Target Patient Population
  • Table 27.7 RSV Vaccine Developers: Distribution by Year of Establishment
  • Table 27.8 RSV Vaccine Developers: Distribution by Company Size
  • Table 27.9 RSV Vaccine Developers: Distribution by Location of Headquarters
  • Table 27.10 Moderna: Consolidated Financial Details, FY 2021 onwards (USD Million)
  • Table 27.11 Pfizer: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (USD Million)
  • Table 27.12 GlaxoSmithKline: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (EUR Million)
  • Table 27.13 Sanofi: Business Segment-wise Revenues and Consolidated Financial Details, FY 2021 onwards (EUR Million)
  • Table 27.14 Clinical Trial Analysis: Distribution by Trial Registration Year, Since 2015
  • Table 27.15 Clinical Trial Analysis: Distribution by Trial Status
  • Table 27.16 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Since 2015
  • Table 27.17 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2015
  • Table 27.18 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 27.19 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Table 27.20 Clinical Trial Analysis: Distribution by Study Design
  • Table 27.21 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 27.22 Clinical Trial Analysis: Distribution by Gender
  • Table 27.23 Clinical Trial Analysis: Distribution by Target Patient Population
  • Table 27.24 Leading Players: Distribution by Number of Registered Trial
  • Table 27.25 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
  • Table 27.26 Clinical Trial Analysis: Distribution by Trial Status and Geography
  • Table 27.27 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
  • Table 27.28 Patent Analysis: Distribution by Patent Publication Year, Since 2020
  • Table 27.29 Patent Analysis: Distribution by Type of Patent
  • Table 27.30 Patent Analysis: Distribution by Type of Patent and Publication Year, Since 2020
  • Table 27.31 Patent Analysis: Distribution by Patent Application Year, Since 2008
  • Table 27.32 Patent Analysis: Distribution by Patent Age
  • Table 27.33 Cumulative Year-wise Distribution by Type of Applicant
  • Table 27.34 Patent Analysis: Distribution by Patent Jurisdiction
  • Table 27.35 Leading Industry Players: Distribution by Number of Patents
  • Table 27.36 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 27.37 Leading Inventors: Distribution by Number of Patents
  • Table 27.38 RSV Vaccines: Patent Valuation
  • Table 27.39 Global RSV Vaccine Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040) (USD Million)
  • Table 27.40 Global RSV Vaccine Market, Forecasted Estimates (Till 2040): Conservative Scenario (USD Million)
  • Table 27.41 Global RSV Vaccine Market, Forecasted Estimates (Till 2040): Optimistic Scenario (USD Million)
  • Table 27.42 RSV Vaccine Market: Distribution by Type of Vaccine
  • Table 27.43 RSV Vaccine Market for Subunit / Viral-like-Particle (VLP) Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.44 RSV Vaccine Market for Live Attenuated / Chimeric Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.45 RSV Vaccine Market for mRNA Vaccines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.46 RSV Vaccine Market: Distribution by Route of Administration
  • Table 27.47 RSV Vaccine Market for Intramuscular, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.48 RSV Vaccine Market for Other Routes, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.49 RSV Vaccine Market: Distribution by Target Patient Population
  • Table 27.50 RSV Vaccine Market for Elderly Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.51 RSV Vaccine Market for Infants / Children, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.52 RSV Vaccine Market for Pregnant Individuals, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.53 RSV Vaccine Market: Distribution by Distribution channel
  • Table 27.54 RSV Vaccine Market for Pharmacies and Drug Stores, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.55 RSV Vaccine Market for Government / Institutional Suppliers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.56 RSV Vaccine Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.57 RSV Vaccine Market: Distribution by Key Geographical Regions
  • Table 27.58 RSV Vaccine Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.59 RSV Vaccine Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2040): Conservative, Base and Optimistic Scenario (USD Million)
  • Table 27.60 Market Movement Analysis: Key Geographical Regions
  • Table 27.61 Penetration Growth Matrix: Key Geographical Regions
  • Table 27.62 RSV Vaccine Market: Distribution by Leading Players